Almac Group Appoints David Taylor as Head of Manufacturing Operations
May 1, 2018
Craigavon, N.I., 01 May 2018 – David Taylor joined the Almac Group in November 2017 as Head of Manufacturing, Almac Sciences. He is tasked with the overall accountability for small molecule API and peptide manufacturing in Craigavon, and delivering on Almac’ Sciences’ supply chain operations at the Northern Ireland site. David has worked in the pharmaceutical and fine chemical industries for over twenty-two years, and brings with him a strong background in both the technical and manufacturing disciplines, allowing him to lead multidisciplinary teams to deliver streamlined operational outcomes. In an industry with significant emphasis on safety, quality and regulatory compliance, David has the skill set needed to anticipate and successfully communicate planning and procurement changes to customers, clients and third-parties abroad.
Dr Charles Shields, VP Peptides & Small Molecule API commented “We are delighted to welcome David to Almac. He clearly brings an impressive track record which is especially important to us as we continue to drive global sales and operational excellence. With his expertise and level of experience he will prove to be a great asset to our senior management team.”
After graduating from Newcastle Polytechnic and completing his PhD and post doctoral studies at the University of Sunderland, David worked as a chemist transferring fine chemicals and API manufacturing processes from lab scale through to full commercial scale. He transferred from R&D into manufacturing, leading large teams of shift operators for the cGMP manufacture of a range of APIs and registered intermediates on a top tier CoMAH site at ChiRex (now Sterling Pharma).
Following that, David gained experience in manufacturing, project and program management and has led teams to deliver projects in pre-clinical process development and multi gram synthesis to early phase multi kilo manufacture and through to late phase full scale process validation, product stability (full ICH study) and regulatory filing submission (DMF, CEP). He has worked at sites around the UK for Piramal Healthcare, Aesica and the Wasdell group.
David latterly gained senior leadership experience in drug product manufacture at Wasdell manufacturing (formerly SCM Pharma) and was accountable on the MHRA and Home office licenses.
About Almac Group
‘Partnering to Advance Human Health’
The Almac Group is an established contract development and manufacturing organization that provides an extensive range of integrated services to the pharmaceutical and biotech sectors globally. The services range from R&D, biomarker discovery development and commercialization, API manufacture, formulation development, clinical trial supply, IXRS® technology (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organization that has organically grown almost 50 years and now employs close to 5600 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with operations in the UK, Ireland, across the US (Pennsylvania, North Carolina and California) and in Asia (Singapore and Tokyo).